NCT05382728招募中3 期
A Phase III, Randomised, Double-blind, Multi-center Study to Assess the Efficacy and Safety of TY-9591 Tablets Versus Osimertinib as First Line Treatment in Patients With EGFR-sensitive Mutation, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 680
- 试验地点
- 2
- 主要终点
- Median Progression Free Survival (PFS)
研究概览
简要总结
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
详细描述
This is a Phase III, double-blind, randomised study assessing the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that is known to be EGFR sensitising mutation (EGFRm) positive, treatment-naïve and eligible for first-line treatment with an EGFR-TKI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 years and <80 years.
- •Locally advanced or metastatic NSCLC diagnosed by histology or cytology.
- •Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites).
- •No prior systemic antitumor therapy for locally advanced or metastatic NSCLC.
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.
- •The ECOG score is 0-1, and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.
- •Adequate bone marrow reserve function, and no liver, kidney and coagulation dysfunction.
- •Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose.
- •Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment.
- •Patients can understand and voluntarily sign the informed consent form.
- •Patient able to comply with study requirements.
排除标准
- •Any of the following treatment:
- •Previous treatment with EGFR inhibitor;
- •Previous treatment with Systematic antitumor therapy (including targeted therapy, biotherapy and immunodrug therapy, etc.)；
- •Previous treatment with standard chemotherapy with 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug;
- •Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis;
- •Uncontrollable or poorly controlled pleural and abdominal effusion;
- •Major surgery within 28 days of the first dose of study treatment;
- •Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4;
- •Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia;
- •Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.
- •Pathologically confirmed squamous cell carcinoma or squamous cell component predominance in NSCLC.
- •Symptomatic brain metastases or leptomeningeal metastases.
- •Patients have spinal cord compression caused by tumor.
- •Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs.
- •Cardiac function and disease are consistent with the following:
- •Corrected QT interval(QTc)≥ 470 milliseconds from 3 times of electrocardiograms (ECGs);
- •Any clinically important abnormalities in rhythm;
- •Any factors that increase the risk of QTc prolongation;
- •Left ventricular ejection fraction (LVEF) <50%.
- •Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.
- •Previous history of interstitial lung disease(ILD), drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.
- •Previous allogeneic bone marrow transplant.
- •Pregnant or lactating women.
- •Any other disease or medical condition that is unstable or may affect the safety or study compliance.
- •Hypersensitivity to investigational drug or similar compounds or excipients.
研究组 & 干预措施
TY-9591+placebo Osimertinib
Experimental
TY-9591 (160mg orally, once daily) plus placebo Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
干预措施: TY-9591 (Drug)
TY-9591+placebo Osimertinib
Experimental
TY-9591 (160mg orally, once daily) plus placebo Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
干预措施: placebo Osimertinib (Drug)
Osimertinib+placebo TY-9591
Active Comparator
Osimertinib (80mg orally, once daily) plus placebo TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
干预措施: Osimertinib (Drug)
Osimertinib+placebo TY-9591
Active Comparator
Osimertinib (80mg orally, once daily) plus placebo TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
干预措施: placebo TY-9591 (Drug)
结局指标
主要结局
Median Progression Free Survival (PFS)
时间窗: approximately 18 months
PFS is defined as time from randomization until the date of first documented disease progression or death due to any cause
次要结局
- Intracranial Overall Response Rate (iORR)(approximately 18 months)
- Intracranial Median Progression Free Survival (iPFS)(approximately 18 months)
- Duration of Response (DoR)(approximately 18 months)
- Clinical Benefit Rate (CBR)(approximately 18 months)
- Overall Survival (OS)(From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months)
- Time To Progress (TTP)(approximately 18 months)
- Plasma Concentrations of TY-9591(approximately 18 months)
- Objective Response Rate (ORR)(approximately 18 months)
- Disease Control Rate (DCR)(approximately 18 months)
- Depth of Response (DepOR)(approximately 18 months)
- Assessment of health-related quality of life (FACT-L)(approximately 18 months)
- Safety variables(Assessments performed throughout the study period)
- Plasma Concentrations of TY-9591-D2(approximately 18 months)
- Plasma Concentrations of TY-9591-D1(approximately 18 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesEGFR Activating MutationBrain MetastasesNSCLCNCT05948813TYK Medicines, Inc420
已完成
1 期
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersHealthy VolunteersNCT04798638TYK Medicines, Inc16
进行中（未招募）
3 期
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsNon-small Cell CarcinomaEGFR Gene MutationNCT04695925Li Zhang, MD294
已完成
3 期
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerAnticancer TreatmentNCT02151981AstraZeneca421
尚未招募
2 期
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNSCLCNCT06672068TYK Medicines, Inc60